NCT04240652Recruiting
The Diabetic Retinopathy Screening, Prevention and Control Program
Source: ClinicalTrials.gov · Last updated 5 Feb 2020 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The greatest harm of diabetes is various acute and chronic complications, especially diabetic retinopathy(DR), leading to extremely high rates of disability and blindness. Early screening, early diagnosis, and early treatment are the keys to maintaining vision in patients with DR. However, compared with the high prevalence of diabetes in China, the DR screening ability is relatively inadequate. To change this situation, deep learning(DL), a form of artificial intelligence (AI), might be a potential effective method to solve this dilemma.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 500000 (estimated)
- First submitted
- 22 Jan 2020
- Start date
- 5 Jun 2018
- Primary completion date
- 5 Jun 2038
- Lead sponsor
- Shanghai Jiao Tong University School of Medicine
- Diseases
- Diabetic eye disease
- NCT number
- NCT04240652
What you commit to
- Study type: Observational
- Planned participants: 500000
- From 5 Jun 2018 to the primary completion date, 5 Jun 2038
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Those who have a history of drug abuse;
- Sexually transmitted diseases such as AIDS and syphilis, and infectious diseases such as viral hepatitis and tuberculosis which are at active phase;
- Any condition that the investigator think that the subject is not suitable for participating in the study.
- For detailed In-/Ex-clusion criteria please see the study protocol.
Who the study is looking for
- Meet the diagnostic criteria for type 2 diabetes according to the World Health Organization (WHO) in 1999; Type 1 diabetes, single gene mutation diabetes, secondary diabetes caused by pancreatic damage, Cushing's syndrome, thyroid dysfunction, or acromegaly;
- Subjects from other medical institutes are diabetes, non-diabetic patients and healthy participants who are invited to participate in the study.
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Ruijin Hospital, Shanghai Jiao Tong University School of Medicine Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
| Shanghai Jiao Tong University School of Medicine Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.